Corline Biomedical AB
Research Corline Biomedical AB (CLBIO) on Bullrun: market cap SEK 474.32M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCLBIO
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 474.32M
- Financial periodQ1 2026
- RevenueSEK 4.29M
- Net income-SEK 2.50M
- Free cash flow-SEK 5.97M
- Gross margin102.2%
Valuation Snapshot
latest market cap is SEK 474.32M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 7.65M | -SEK 14.71M | -SEK 18.67M | 81.4% | -0.6 | SEK 20.56M | n/a | SEK 93.76M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | SEK 474.32M | n/a | n/a | n/a |
About Corline Biomedical AB
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on Corline Heparin Conjugate (CHC) technology, a naturally occurring biomolecule heaparin, which is routinely used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Corline Biomedical AB's market cap?
Corline Biomedical AB's market capitalization is SEK 474.32M.
What does Corline Biomedical AB do?
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on Corline Heparin Conjugate (CHC) technology, a naturally occurring biomolecule heaparin, which is routinely used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting.